Relations of serum COMP to cardiovascular risk factors and endothelial function in patients with rheumatoid arthritis treated with methotrexate and TNF-α inhibitors

Journal of Rheumatology

Volumn 39, Issue 7, 2012, Pages 1341-1347

  Hjeltnes, Gunnbjørg ^a   Hollan, Ivana ^a   Førre, Øystein ^b   Wiik, Allan ^c   Lyberg, Torstein ^b   Mikkelsen, Knut ^a   Agewall, Stefan ^b  

^a Hospital for Rheumatic Diseases   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

Anticitrullinated protein antibodies; Cartilage oligomeric matrix protein; Endothelial function; Reactive hyperemic index; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GLUCOCORTICOIDS; GLYCOPROTEINS; HUMANS; HYPEREMIA; MALE; METHOTREXATE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863505041     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.111401     Document Type: Article

References (31)

1. Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys PE, Kerstens PJ, et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis 2010;69:1333-7.
2. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373:659-72.
3. de Jong Z, Munneke M, Vilim V, Zwinderman AH, Kroon HM, Ronday HK, et al. Value of serum cartilage oligomeric matrix protein as a prognostic marker of large-joint damage in rheumatoid arthritis - Data from the RAPIT study. Rheumatology 2008;47:868-71. (Pubitemid 351796375)
4. Lindqvist E, Eberhardt K, Bendtzen K, Heinegård D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64:196-201. (Pubitemid 40193611)
5. Saxne T, Heinegård D. Cartilage oligomeric matrix protein: A novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 1992;31:583-91.
6. Posey K, Coustry F, Hecht JT, Lawler J. Cartilage oligomeric matrix protein (Mouse). UCSD Nature Molecule Pages 4 Nov 2010. [Epub ahead of print]
7. Syversen SW, Goll GL, van der Heijde D, Landewé R, Lie BA, Odegård S, et al. Cartilage and bone biomarkers in rheumatoid arthritis: Prediction of 10-year radiographic progression. J Rheumatol 2009;36:266-72.
8. Månsson B, Carey D, Alini M, Ionescu M, Rosenberg LC, Poole AR, et al. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995;95:1071-7.
9. Fujikawa K, Kawakami A, Tamai M, Uetani M, Takao S, Arima K, et al. High serum cartilage oligomeric matrix protein determines the subset of patients with early-stage rheumatoid arthritis with high serum C-reactive protein, matrix metalloproteinase-3, and MRI-proven bone erosion. J Rheumatol 2009;3:1126-9.
10. Crnkic M, Månsson B, Larsson L, Geborek P, Heinegård D, Saxne T. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res Ther 2003;5:R181-5.
11. Morozzi G, Fabbroni M, Bellisai F, Cucini S, Simpatico A, Galeazzi M. Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis. Clin Rheumatol 2007;26:1335-8. (Pubitemid 47034192)
12. Riessen R, Fenchel M, Chen H, Axel DI, Karsch KR, Lawler J. Cartilage oligomeric matrix protein (thrombospondin-5) is expressed by human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001;21:47-54. (Pubitemid 32061926)
13. Wang L, Wang X, Kong W. ADAMTS-7, a novel proteolytic culprit in vascular remodeling. Sheng Li Xue Bao 2010;62:285-94.
14. Du Y, Wang Y, Wang L, Liu B, Tian Q, Liu CJ, et al. Cartilage oligomeric matrix protein inhibits vascular smooth muscle calcification by interacting with bone morphogenetic protein-2. Circ Res 2011;108:917-28.
15. Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006;65:1608-12. (Pubitemid 44799673)
16. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303-7. (Pubitemid 36314415)
17. Goodson NJ, Wiles NJ, Lunt M, Barret EM, Silman AJ, Symmons PM. Mortality in early inflammatory polyarthritis. Arthritis Rheum 2002;46:2010-9.
18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
19. Hjeltnes G, Hollan I, Førre Ø, Wiik A, Mikkelsen K, Agewall S. Anti-CCP and RF IgM - Predictors of impaired endothelial function in RA patients. Scand J Rheumatol 2011;40:422-7.
20. Salaffi F, Cimmino MA, Leardini G, Gasparini S, Grassi W. Disease activity assessment of rheumatoid arthritis in daily practice: Validity, internal consistency, reliability and congruency of the Disease Activity Score including 28 joints (DAS28) compared with the Clinical Disease Activity Index (CDAI). Clin Exp Rheumatol 2009;27:552-9.
21. Uhlig T, Haavardsholm EA, Kvien TK. Comparison of the Health Assessment Questionnaire (HAQ) and the modified HAQ (MHAQ) in patients with rheumatoid arthritis. Rheumatology 2006;45:454-8.
22. Kuvin JT, Patel AR, Sliney KA, Pandian NG, Sheffy J, Schnall RP, et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J 2003;146:161-72.
23. Bonetti PO, Barsness GW, Keelan PC, Schnell TI, Pumper GM, Kuvin JT, et al. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol 2003;41:1761-8. (Pubitemid 36584250)
24. Rozanski A, Qureshi E, Bauman M, Reed G, Pillar G, Diamond GA. Peripheral arterial responses to treadmill exercise among healthy subjects and atherosclerotic patients. Circulation 2001;103:2084-9. (Pubitemid 32373012)
25. Christensen AF, Lindegaard H, Hørslev-Petersen K, Hetland ML, Ejbjerg B, Stengaard-Pedersen K, et al. Cartilage oligomeric matrix protein associates differentially with erosions and synovitis and has a different temporal course in cyclic citrullinated peptide antibody (anti-CCP)-positive versus anti-CCP-negative early rheumatoid arthritis. J Rheumatol 2011;38:1563-8.
26. den Broeder AA, Joosten LA, Saxne T, Heinegård D, Fenner H, Miltenburg AM, et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: Effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002;61:311-8. (Pubitemid 34257741)
27. Kawashiri SY, Kawakami A, Ueki Y, Imazato T, Iwamoto N, Fujikawa K, et al. Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: Comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab. Joint Bone Spine 2010;77:418-20.
28. Happonen KE, Saxne T, Aspberg A, Mörgelin M, Heinegård D, Blom AM. Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis. Arthritis Rheum 2010;62:3574-83.
29. Skoumal M, Haberhauer G, Feyertag J, Kittl EM, Bauer K, Dunky A. Serum levels of cartilage oligomeric matrix protein (COMP): A rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment. Rheumatol Int 2006;26:1001-4. (Pubitemid 44394502)
30. Mierau R, Genth E. Diagnosis and prognosis of early rheumatoid arthritis, with special emphasis on laboratory analysis. Clin Chem Lab Med 2006;44:138-43. (Pubitemid 43237955)
31. Trouw LA, Haisma EM, Levarht EW, van der Woude D, Ioan-Facsinay A, Daha MR, et al. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum 2009;60:1923-31.